Evidence map›Paper›PMID 34359656›Full record

ArticleCancers2021

Cytoplasmic Localization of RXRα Determines Outcome in Breast Cancer.

Alaleh Zati Zehni, Falk Batz, Vincent Cavaillès, Sophie Sixou, Till Kaltofen, Simon Keckstein, Helene Hildegard Heidegger, Nina Ditsch, Sven Mahner, Udo Jeschke and 1 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Alaleh Zati ZehniDepartment of Obstetrics and Gynecology, University Hospital Munich LMU, 81377 Munich, Germany.
Falk BatzDepartment of Obstetrics and Gynecology, University Hospital Munich LMU, 81377 Munich, Germany.
Vincent CavaillèsIRCM-Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université Montpellier, Parc Euromédecine, 208 rue des Apothicaires, CEDEX 5, F-34298 Montpellier, France.ORCID 0000-0002-7160-3074
Sophie SixouFaculté des Sciences Pharmaceutiques, Université Paul Sabatier Toulouse III, CEDEX 09, 31062 Toulouse, France.
Till KaltofenDepartment of Obstetrics and Gynecology, University Hospital Munich LMU, 81377 Munich, Germany.ORCID 0000-0003-1137-211X
Simon KecksteinDepartment of Obstetrics and Gynecology, University Hospital Munich LMU, 81377 Munich, Germany.
Helene Hildegard HeideggerDepartment of Obstetrics and Gynecology, University Hospital Munich LMU, 81377 Munich, Germany.
Nina DitschDepartment of Obstetrics and Gynecology, University Hospital, 86156 Augsburg, Germany.
Sven MahnerDepartment of Obstetrics and Gynecology, University Hospital Munich LMU, 81377 Munich, Germany.
Udo JeschkeDepartment of Obstetrics and Gynecology, University Hospital Munich LMU, 81377 Munich, Germany.ORCID 0000-0003-2623-3235
Theresa VilsmaierDepartment of Obstetrics and Gynecology, University Hospital Munich LMU, 81377 Munich, Germany.ORCID 0000-0003-0452-1148
LMU Klinikum · DEUniversity Hospital Augsburg · DECentre National de la Recherche Scientifique · FRInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this retrospective study was to assess the prognostic value of cytoplasmic versus nuclear RXRα expression in breast cancer (BC) tissue samples and to correlate the results with clinicopathological parameters. In 319 BC patients, the expression of RXRα was evaluated via immunohistochemistry. Prognosis-determining aspects were calculated through uni- and multivariate analyses. Correlation analysis revealed a trend association with nuclear RXRα expression regarding an improved overall survival (OS) (

Indexed as

breast cancerdisease-free survivalimmunohistochemistryoverall survivalprognosisretinoid X receptorsteroid hormone receptorsubcellular localization

Identifiers

PMID34359656
PMCPMC8345077
OpenAlexW3184817799

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.